Stock listing
NASDAQ:RAPP Rapport Therapeutics, Inc. Stock
Home listing (NASDAQ) of Rapport Therapeutics, Inc.
Follow Rapport Therapeutics, Inc. into a list and get an email when it puts out news.
Share price · NASDAQ:RAPP
$23.16 USD -0.24 (-1.0%)
Close on Nov 20, 2026
- Day range
- $23.00 – $23.83 USDNov 20, 2026
- Volume
- 437,720 sharesNov 20, 2026
- Market cap
- $1.37B USDAt the close on Nov 20, 2026 · price × 59.28M shares outstanding
- 52-week range
- $22.06 – $52.93 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $23.30M USDMedian day 437,700 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:RAPP · Home | $23.16 USD | -0.24 (-1.0%) | 437,720 | $23.23 | $23.83 | $23.00 | $23.40 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:RAPP · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $23.16 | -0.24 | -1.0% | $23.23 | $23.83 | $23.00 | 437,720 | |
| $23.40 | -0.36 | -1.5% | $23.70 | $25.00 | $22.91 | 731,089 | |
| $23.76 | -1.06 | -4.3% | $24.66 | $24.88 | $23.41 | 522,764 | |
| $24.82 | -1.33 | -5.1% | $25.78 | $26.14 | $24.63 | 462,563 | |
| $26.15 | +0.30 | +1.2% | $25.85 | $26.29 | $25.11 | 315,633 | |
| $25.85 | -1.17 | -4.3% | $26.76 | $26.90 | $25.45 | 568,187 | |
| $27.02 | +1.06 | +4.1% | $26.06 | $27.10 | $25.77 | 626,291 | |
| $25.96 | -0.11 | -0.4% | $25.83 | $26.90 | $25.30 | 660,143 | |
| $26.07 | +1.63 | +6.7% | $24.50 | $26.35 | $24.06 | 789,005 | |
| $24.44 | +0.72 | +3.0% | $23.72 | $24.52 | $22.95 | 866,405 | |
| $23.72 | -2.21 | -8.5% | $25.64 | $25.67 | $23.67 | 706,810 | |
| $25.93 | +0.49 | +1.9% | $26.12 | $26.36 | $25.27 | 956,000 | |
| $25.44 | +0.31 | +1.2% | $25.39 | $26.06 | $25.13 | 822,403 | |
| $25.13 | +0.08 | +0.3% | $25.16 | $26.16 | $24.22 | 1,327,415 | |
| $25.05 | +0.84 | +3.5% | $23.94 | $25.43 | $23.86 | 922,247 | |
| $24.21 | +1.71 | +7.6% | $22.58 | $25.76 | $22.58 | 3,094,708 | |
| $22.50 | -5.04 | -18.3% | $22.59 | $23.94 | $22.06 | 5,940,919 | |
| $27.54 | +2.21 | +8.7% | $25.11 | $28.31 | $25.11 | 601,911 | |
| $25.33 | -0.60 | -2.3% | $26.02 | $27.95 | $25.10 | 1,040,733 | |
| $25.93 | -0.60 | -2.3% | $27.54 | $27.76 | $25.71 | 1,185,000 | |
| $26.53 | +1.47 | +5.9% | $26.17 | $27.89 | $25.81 | 1,458,200 | |
| $25.06 | -4.31 | -14.7% | $29.91 | $29.91 | $24.69 | 2,158,300 | |
| $29.37 | +0.77 | +2.7% | $30.33 | $31.31 | $26.73 | 8,200,200 | |
| $28.60 | +1.03 | +3.7% | $27.57 | $29.10 | $27.57 | 299,900 | |
| $27.57 | -2.00 | -6.8% | $29.50 | $29.75 | $26.93 | 412,100 | |
| $29.57 | +1.24 | +4.4% | $29.12 | $30.48 | $28.68 | 334,900 | |
| $28.33 | -0.66 | -2.3% | $28.71 | $29.31 | $28.10 | 304,000 | |
| $28.99 | -1.16 | -3.8% | $30.00 | $30.01 | $28.68 | 310,000 | |
| $30.15 | -0.50 | -1.6% | $30.65 | $30.99 | $30.00 | 127,100 | |
| $30.65 | +0.80 | +2.7% | $29.73 | $31.20 | $29.50 | 247,900 | |
| $29.85 | -1.01 | -3.3% | $30.62 | $30.62 | $29.45 | 236,800 | |
| $30.86 | -0.29 | -0.9% | $30.81 | $31.35 | $30.46 | 315,000 | |
| $31.15 | -1.04 | -3.2% | $32.92 | $34.00 | $30.01 | 235,600 | |
| $32.19 | +0.02 | +0.1% | $32.22 | $32.71 | $31.53 | 198,500 | |
| $32.17 | -0.66 | -2.0% | $33.33 | $34.48 | $31.77 | 276,300 | |
| $32.83 | -0.77 | -2.3% | $33.52 | $34.32 | $32.80 | 326,800 | |
| $33.60 | +0.58 | +1.8% | $33.17 | $34.05 | $32.62 | 581,700 | |
| $33.02 | -0.42 | -1.3% | $33.25 | $33.66 | $32.12 | 626,100 | |
| $33.44 | -0.47 | -1.4% | $33.48 | $34.00 | $32.36 | 552,300 | |
| $33.91 | +0.08 | +0.2% | $33.80 | $34.89 | $33.05 | 711,800 | |
| $33.83 | -0.30 | -0.9% | $34.15 | $34.21 | $31.58 | 848,500 | |
| $34.13 | -7.34 | -17.7% | $41.01 | $41.47 | $33.38 | 743,700 | |
| $41.47 | +1.81 | +4.6% | $39.97 | $41.55 | $37.94 | 900,200 | |
| $39.66 | -0.79 | -2.0% | $40.70 | $42.18 | $39.11 | 617,000 | |
| $40.45 | -1.50 | -3.6% | $41.89 | $43.00 | $40.29 | 998,100 | |
| $41.95 | +0.56 | +1.4% | $42.13 | $42.90 | $41.39 | 397,300 | |
| $41.39 | -1.29 | -3.0% | $42.82 | $43.67 | $41.23 | 387,000 | |
| $42.68 | -1.32 | -3.0% | $43.87 | $43.98 | $41.76 | 189,300 | |
| $44.00 | +0.38 | +0.9% | $44.30 | $44.90 | $43.36 | 196,900 | |
| $43.62 | +0.16 | +0.4% | $44.21 | $44.30 | $43.01 | 251,800 | |
| $43.46 | -0.425 | -1.0% | $43.35 | $44.00 | $42.65 | 319,300 | |
| $43.89 | -2.205 | -4.8% | $45.17 | $45.42 | $43.13 | 437,700 | |
| $46.09 | +0.32 | +0.7% | $45.01 | $47.00 | $44.67 | 489,400 | |
| $45.77 | -1.88 | -3.9% | $47.63 | $48.00 | $45.52 | 279,900 | |
| $47.65 | -1.04 | -2.1% | $48.85 | $49.14 | $47.08 | 277,000 | |
| $48.69 | +0.13 | +0.3% | $48.50 | $50.34 | $47.73 | 294,700 | |
| $48.56 | -0.11 | -0.2% | $48.17 | $49.38 | $47.90 | 148,600 | |
| $48.67 | -0.10 | -0.2% | $48.72 | $49.33 | $47.51 | 221,000 | |
| $48.77 | -2.06 | -4.1% | $50.15 | $50.68 | $48.37 | 332,700 | |
| $50.83 | -1.67 | -3.2% | $51.88 | $52.93 | $50.60 | 382,800 | |
| $52.50 | +1.33 | +2.6% | $50.95 | $52.83 | $50.01 | 275,300 | |
| $51.17 | +1.84 | +3.7% | $49.88 | $51.38 | $49.00 | 324,500 | |
| $49.33 | +1.09 | +2.3% | $48.16 | $50.34 | $47.44 | 365,422 | |
| $48.24 | +0.39 | +0.8% | $48.36 | $48.50 | $47.48 | 140,900 | |
| $47.85 | -1.22 | -2.5% | $48.58 | $48.78 | $47.00 | 323,700 |
- Ticker
- NASDAQ:RAPP
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Nov 4, 2026
Rapport Therapeutics Reports Third Quarter 2026 Financials and Provides Business Update
Latest deck · Oct 20, 2026
Corporate Update (October 2026)
Corporate update · 26 slides
Latest news
Rapport Therapeutics Reports Third Quarter 2026 Financials and Provides Business Update
Nov 4, 2026
Closed $25.93 (+1.9%) on Nov 4, 2026
Rapport Therapeutics to Participate in Upcoming Investor Conferences
Nov 3, 2026
Closed $25.44 (+1.2%) on Nov 3, 2026
Rapport Announces Closing of Public Offerings of Common Stock and Pre-Funded Warrants and Convertible Notes, Including Full Exercise of Underwriters’ Options to Purchase Additional Shares and Notes, as well as Concurrent Private Placement
Nov 2, 2026
Closed $25.13 (+0.3%) on Nov 2, 2026
Rapport Announces Pricing of Underwritten Offerings of Common Stock and Pre-Funded Warrants and Convertible Notes and Concurrent Private Placement
Oct 28, 2026
Closed $22.50 (-18.3%) on Oct 28, 2026
Rapport Announces Proposed Public Offerings of Common Stock and Convertible Notes as well as Concurrent Private Placement
Oct 27, 2026
Closed $22.50 (-18.3%) on Oct 28, 2026
Rapport Therapeutics Announces Positive Topline Results from its Phase 2 Trial of RAP-219 for the Treatment of Bipolar Mania
Oct 20, 2026
Closed $29.37 (+2.7%) on Oct 20, 2026
Rapport Therapeutics to Host Virtual KOL Event on the Unmet Need in Bipolar Mania and the RAP-219 Clinical Program
Aug 24, 2026
Closed $49.33 (+2.3%) on Aug 24, 2026
Rapport Therapeutics Reports Second Quarter 2026 Financials and Provides Business Update
Aug 5, 2026
Closed $42.44 (+0.6%) on Aug 5, 2026
Rapport Therapeutics to Participate in the Jefferies Global Healthcare Conference and Goldman Sachs 47th Annual Global Healthcare Conference
May 20, 2026
Closed $36.70 (+2.7%) on May 21, 2026
Rapport Therapeutics Reports First Quarter 2026 Financials and Provides Business Update
May 7, 2026
Closed $39.93 (+7.7%) on May 7, 2026
Rapport Therapeutics, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 19 in the last 12 months · 44 in all · newest Nov 4, 2026 · oldest 2024
- Decks
- 11 decks · latest Oct 20, 2026
Where Rapport Therapeutics, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:RAPP · Home listing · This page | NASDAQ | United States | USD |
| BOATS:RAPP | BOATS | United States | USD |
Valuation
EV/sales 49.4× against a median of 19.0×: 8th lowest of 10 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $987.3M USD
- P/E
- Loss
- EV/sales
- 49.4×
- EV/EBITDA
- Negative EBITDA
- Price/book
- 3.5×
- Gross margin
- Not reported
- Operating margin
- −838.1%
- Net margin
- −752.4%
- Debt to equity
- 0.0×
- Beta vs S&P 500
- 1.16
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Rapport Therapeutics, Inc. · NASDAQ:RAPP | US$1.37B | US$987.3M | n/a | 49.4× | n/a | 3.5× | −752.4% | 0.0× | 1.16 |
| Sarepta Therapeutics, Inc. · NASDAQ:SRPT | US$1.43B | US$1.41B | n/a | 0.7× | n/a | 0.9× | −5.9% | 0.6× | 1.70 |
| ADARx Pharmaceuticals, Inc. · NASDAQ:ADRX | US$1.42B | US$521.8M | n/a | 77.6× | n/a | 2.5× | n/a | 0.0× | n/a |
| Nurix Therapeutics, Inc. · NASDAQ:NRIX | US$1.40B | US$683.6M | 4.8× | 1.0× | n/a | 1.4× | 42.0% | 0.0× | 1.15 |
| Intellia Therapeutics, Inc. · NASDAQ:NTLA | US$1.40B | US$1.00B | n/a | 19.0× | n/a | 2.3× | −805.7% | 0.1× | 2.01 |
| Tyra Biosciences, Inc. · NASDAQ:TYRA | US$1.39B | US$694.9M | n/a | n/a | n/a | 2.0× | n/a | 0.0× | 0.40 |
| Wuhan Healthgen Biotechnology Corp Class A · SSE:688765 | US$1.37B | US$1.37B | n/a | 164× | n/a | 3.3× | −252.8% | 0.1× | n/a |
| Immunocore Holdings plc · NASDAQ:IMCR | US$1.36B | US$463.6M | n/a | 1.1× | n/a | 3.3× | −7.5% | 0.0× | 0.62 |
| Nanobiotix SA · EURONEXT:NANO | US$1.36B | US$1.36B | n/a | 41.7× | n/a | n/a | −80.8% | n/a | n/a |
| uniQure N.V. · NASDAQ:QURE | US$1.36B | US$739.1M | n/a | 36.6× | n/a | 4.6× | n/a | 0.2× | 1.25 |
| UroGen Pharma Ltd. · NASDAQ:URGN | US$1.36B | US$1.46B | n/a | 5.8× | n/a | n/a | −26.3% | n/a | 1.23 |
| Median of the others | US$1.38B | US$871.1M | 4.8× | 19.0× | 2.4× | −26.3% | 0.1× | 1.23 |
Forecasts
15 strong buy · 1 buy · Analysts' consensus from EODHD, read Nov 19, 2026. Not 6ix's view and not investment advice.
- Price target
- 64.21 USD · Analysts' mean
- EPS, year to Dec 2026
- -3.25 · 12 analysts
- Revenue, year to Dec 2026
- 20.01M · 15 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Troy Ignelzi | Chief Financial Officer |
| Abe Ceesay | President |
| Cheryl Gault | Chief Operating Officer |
| David Bredt | Founder, Chief Scientific Officer |
| Jeffrey Sevigny | Chief Medical Officer |
| Kathy Wilkinson | Chief People Officer |
| Steve Paul | Founder; Chairman, Board of Directors |
| Swamy Yeleswaram | Chief Development Officer |
Board
| Director | Role |
|---|---|
| Steve Paul | Founder; Chairman, Board of Directors |
| John Maraganore | Venture Partner, ARCH Venture Partners and Atlas Ventures |
| Reid Huber | Partner, Third Rock Ventures |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 4, 2026 · Before open | +1.9% |
| Q2 2026 | Aug 5, 2026 · Before open | +0.6% |
| Q1 2026 | May 7, 2026 · Before open | +7.7% |
| Q4 2025 | Mar 17, 2026 | −4.1% |
| Q3 2025 | Nov 6, 2025 · Before open | −3.1% |
| Q2 2025 | Aug 7, 2025 · Before open | +5.5% |
| Q1 2025 | May 8, 2025 · Before open | +4.2% |
| Q4 2024 | Mar 11, 2025 | +21.0% |
| Q3 2024 | Nov 7, 2024 · Before open | +2.9% |
| Q2 2024 | Aug 8, 2024 · Before open | −1.6% |
All 11 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 29, 2024 |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Corporate Update (October 2026) | Corporate update | 26 slides | Oct 20, 2026 |
| Investor Presentation (August 2026) | Investor deck | 51 slides | August 2026 |
| American Academy of Neurology Annual Meeting 2026 | Conference | 13 slides | Apr 21, 2026 |
| Investor Presentation (April 2026) | Investor deck | 50 slides | Apr 21, 2026 |
| Investor Presentation (January 2026) | Investor deck | 47 slides | Jan 7, 2026 |
| Technical Presentation (September 2025) | Technical | 22 slides | Sep 8, 2025 |
| Investor Presentation (August 2025) | Investor deck | 32 slides | Aug 7, 2025 |
| Investor Day (June 2025) | Investor day | 46 slides | Jun 2, 2025 |
| Investor Presentation (March 2025) | Investor deck | 38 slides | Mar 3, 2025 |
| Epilepsy Foundation Pipeline Conference 2024 | Conference | 8 slides | Sep 25, 2024 |
All 11 decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (May 2024) | Investor deck | 40 slides | May 2024 |
Financings
| Raise | Date |
|---|---|
| At-the-market programme of common stock Closed: US$10M raised · US$25.05 a share | Nov 4, 2026 |
| Public offering of common stock and pre-funded warrants Closed: US$175M raised · US$21 a share · Morgan Stanley +4 Dealers: Morgan Stanley (co-lead), Leerink Partners (co-lead), Evercore ISI (co-lead), BTIG (co-lead), Citizens Capital Markets (co-lead) Use of proceeds: Fund clinical trials of RAP-219, other research and development, working capital and general corporate purposes | Nov 2, 2026 |
| 2.25% convertible senior notes due 2032 Closed: US$172.5M raised · Morgan Stanley +2 Dealers: Morgan Stanley (co-lead), Leerink Partners (co-lead), Evercore ISI (co-lead) Use of proceeds: Fund clinical trials of RAP-219, other research and development, working capital and general corporate purposes | Nov 2, 2026 |
| Private placement of common stock Closed: US$30M raised · US$21 a share · Morgan Stanley +2 Dealers: Morgan Stanley, Leerink Partners, Evercore ISI Use of proceeds: Fund clinical trials of RAP-219, other research and development, working capital and general corporate purposes | Nov 2, 2026 |
| Public offering of common stock Update: about US$250M · US$26 a share · Goldman Sachs & Co. LLC +3 Dealers: Goldman Sachs & Co. LLC (co-lead), Jefferies (co-lead), TD Cowen (co-lead), Stifel (co-lead) | Sep 9, 2025 |
Open Financings · Read by 6ix AI from the company's releases
IPO
Priced at US$17.00 a share on Jun 6, 2024.
- Price
- US$17.00 a share
- Shares offered
- 8,000,000 shares of common stock
- Offering size
- US$136 million
- Underwriters' option
- Up to 1,200,000 more shares
- Underwriters
- Goldman Sachs & Co. LLC, Jefferies, TD Cowen, Stifel · In the order on the cover
- Shares delivered
- On or about Jun 10, 2024
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | Mar 27, 2024 |
| Filed publicly | May 17, 2024 |
| Amended once | Jun 3, 2024 |
| Shares registered with an exchange | Jun 4, 2024 |
| Declared effective by the SEC | Jun 6, 2024 |
| Final prospectus, with the price | Jun 7, 2024 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Jun 7, 2024 |
| EFFECT · Notice that a registration is effective | Jun 6, 2024 |
| CERT · Exchange's certificate of listing | Jun 6, 2024 |
| 8-A12B · Registration of shares for listing on an exchange | Jun 4, 2024 |
| CORRESP · Letter to the SEC | Jun 4, 2024 |
| CORRESP · Letter to the SEC | Jun 4, 2024 |
| CORRESP · Letter to the SEC | Jun 3, 2024 |
| S-1/A · Registration statement, amended | Jun 3, 2024 |
| CORRESP · Letter to the SEC | May 29, 2024 |
| UPLOAD · Letter from the SEC | May 24, 2024 |
All 17 filings
| Filing | Filed |
|---|---|
| CORRESP · Letter to the SEC | May 17, 2024 |
| S-1 · Registration statement | May 17, 2024 |
| UPLOAD · Letter from the SEC | May 13, 2024 |
| DRSLTR · Letter to the SEC with a draft | Apr 29, 2024 |
| DRS/A · Draft registration statement, amended | Apr 29, 2024 |
| UPLOAD · Letter from the SEC | Apr 24, 2024 |
| DRS · Draft registration statement | Mar 27, 2024 |
Open IPO · From the cover of the final prospectus (424B4) filed Jun 7, 2024
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | |
| Cost of revenue | 1.02M | 839.0K | 112.0K | 15.0K |
| Gross profit | -1.02M | -839.0K | -112.0K | -15.0K |
| Research and development | 94.8M | 60.9M | 28.0M | 9.12M |
| Selling, general and administrative | 30.3M | 22.1M | 8.18M | 1.37M |
| Operating income | -125.1M | -83.1M | -36.2M | -10.4M |
| Depreciation and amortization | 1.02M | 839.0K | 112.0K | 15.0K |
| EBITDA | -124.1M | -82.2M | -36.1M | -10.4M |
| Interest expense | 0 | 285.0K | ||
| Income before tax | -111.5M | -78.3M | -34.8M | -10.7M |
| Income tax | 0 | 0 | 10.0K | |
| Net income | -111.5M | -78.3M | -34.8M | -10.7M |
| Earnings per share, basic | -2.86 | -3.78 | -23.10 | -0.53 |
| Earnings per share, diluted | -2.86 | -3.78 | -23.10 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Cash and equivalents | 52.6M | 56.8M | 70.2M | 31.2M |
| Short-term investments | 437.9M | 248.5M | 77.3M | 0 |
| Receivables | 0 | |||
| Current assets | 498.6M | 309.8M | 150.9M | 31.3M |
| Property, plant and equipment | 2.98M | 3.53M | 1.92M | |
| Total assets | 512.4M | 314.9M | 155.4M | 31.6M |
| Accounts payable | 4.19M | 1.95M | 2.50M | 1.45M |
| Current liabilities | 19.0M | 8.77M | 8.80M | 1.66M |
| Total debt | 11.5M | 1.48M | 2.15M | 10.4M |
| Total liabilities | 27.8M | 9.51M | 14.5M | 12.1M |
| Shareholders' equity | 484.7M | 305.4M | -25.6M | 19.5M |
| Shares outstanding | 47.8M | 36.6M | 4.17M | 20.1M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Cash from operations | -87.5M | -64.8M | -27.2M | -3.24M |
| Capital spending | -616.0K | -2.40M | -1.64M | -284.0K |
| Free cash flow | -88.1M | -67.2M | -28.8M | -3.53M |
| Cash from investing | -187.5M | -170.1M | -78.9M | -5.28M |
| Cash from financing | 270.8M | 221.6M | 145.1M | 39.7M |
| Share buybacks | -1.00K | 0 | -4.00K | |
| Change in cash | -4.16M | -13.3M | 39.1M | 31.2M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 16, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 4, 2026 | Quarterly report | SEC |
| 8-K · Current report | Nov 4, 2026 | Results | SEC |
| 4 · Change in ownership | Nov 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 30, 2026 | Insider trade | SEC |
| 8-K · Current report | Oct 30, 2026 | Results | SEC |
| 424B5 · Prospectus | Oct 30, 2026 | Offer document | SEC |
| 424B5 · Prospectus | Oct 30, 2026 | Offer document | SEC |
| 305B2 | Oct 29, 2026 | Other filings | SEC |
| FWP · Free writing prospectus | Oct 28, 2026 | Offer document | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| FWP · Free writing prospectus | Oct 28, 2026 | Offer document | SEC |
| FWP · Free writing prospectus | Oct 27, 2026 | Offer document | SEC |
| FWP · Free writing prospectus | Oct 27, 2026 | Offer document | SEC |
| 424B5 · Prospectus | Oct 27, 2026 | Offer document | SEC |
| 424B5 · Prospectus | Oct 27, 2026 | Offer document | SEC |
| 4 · Change in ownership | Oct 23, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 23, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 22, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 22, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 22, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 22, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 21, 2026 | Insider trade | SEC |
| 8-K · Current report | Oct 20, 2026 | Current report | SEC |
| 4 · Change in ownership | Oct 8, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Oct 6, 2026 | Other filings | SEC |
| 4 · Change in ownership | Oct 1, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Sep 30, 2026 | Other filings | SEC |
| 4 · Change in ownership | Sep 24, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 9, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 26, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 26, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Aug 25, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Aug 24, 2026 | Other filings | SEC |
| 4 · Change in ownership | Aug 20, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Aug 19, 2026 | Other filings | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Aug 12, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 12, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Aug 5, 2026 | Quarterly report | SEC |
| 8-K · Current report | Aug 5, 2026 | Results | SEC |
| 4 · Change in ownership | Jul 29, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 15, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 1, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 1, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jun 30, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jun 29, 2026 | Other filings | SEC |
| 4 · Change in ownership | Jun 10, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 10, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 10, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 10, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 10, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 10, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 10, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 10, 2026 | Insider trade | SEC |
| 8-K · Current report | Jun 10, 2026 | Meeting outcome | SEC |
| 4 · Change in ownership | May 28, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | May 27, 2026 | Other filings | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | May 13, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 11, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | May 11, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | May 8, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | May 7, 2026 | Other filings | SEC |
| 10-Q · Quarterly report | May 7, 2026 | Quarterly report | SEC |
| 8-K · Current report | May 7, 2026 | Results | SEC |
| ARS · Annual report to shareholders | Apr 23, 2026 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 23, 2026 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 23, 2026 | Meeting notice | SEC |
| 4 · Change in ownership | Apr 21, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 21, 2026 | Insider trade | SEC |
| 8-K · Current report | Apr 21, 2026 | Current report | SEC |
| 144 · Notice of proposed sale | Apr 17, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Apr 17, 2026 | Other filings | SEC |
| 4 · Change in ownership | Apr 14, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Apr 13, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Apr 10, 2026 | Other filings | SEC |
| 4 · Change in ownership | Apr 9, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Apr 8, 2026 | Other filings | SEC |
| 4 · Change in ownership | Mar 31, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Mar 30, 2026 | Other filings | SEC |
| 4 · Change in ownership | Mar 26, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Mar 25, 2026 | Other filings | SEC |
| S-3ASR · Registration statement | Mar 10, 2026 | Offer document | SEC |
| S-8 · Registration statement for employee plans | Mar 10, 2026 | Offer document | SEC |
| 10-K · Annual report | Mar 10, 2026 | Annual report | SEC |
| 8-K · Current report | Mar 10, 2026 | Results | SEC |
| 4 · Change in ownership | Mar 9, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Mar 5, 2026 | Other filings | SEC |
| 4 · Change in ownership | Feb 19, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 19, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 17, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Feb 4, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 4, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 4, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 4, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 4, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 4, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 22, 2026 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | Jan 21, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Jan 16, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jan 15, 2026 | Other filings | SEC |
| 8-K · Current report | Jan 7, 2026 | Current report | SEC |
| 424B5 · Prospectus | Jan 7, 2026 | Offer document | SEC |
| 8-K · Current report | Jan 7, 2026 | Current report | SEC |
| 4 · Change in ownership | Jan 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 5, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jan 2, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jan 2, 2026 | Other filings | SEC |
| 4 · Change in ownership | Dec 18, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Dec 17, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Dec 17, 2025 | Other filings | SEC |
| 4 · Change in ownership | Dec 16, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 1, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 18, 2025 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 14, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 6, 2025 | Quarterly report | SEC |
| 8-K · Current report | Nov 6, 2025 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Oct 22, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Oct 16, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Oct 16, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Oct 15, 2025 | Other filings | SEC |
| 4 · Change in ownership | Sep 19, 2025 | Insider trade | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Sep 18, 2025 | Big-stake notice | SEC |
| 144 · Notice of proposed sale | Sep 17, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Sep 17, 2025 | Other filings | SEC |
| 4 · Change in ownership | Sep 17, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 15, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 15, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 11, 2025 | Insider trade | SEC |
| 8-K · Current report | Sep 10, 2025 | Material contract | SEC |
| 424B5 · Prospectus | Sep 10, 2025 | Offer document | SEC |
| 4 · Change in ownership | Sep 10, 2025 | Insider trade | SEC |
| 424B5 · Prospectus | Sep 8, 2025 | Offer document | SEC |
| 144 · Notice of proposed sale | Sep 8, 2025 | Other filings | SEC |
| 8-K · Current report | Sep 8, 2025 | Current report | SEC |
| 8-K · Current report | Sep 8, 2025 | Current report | SEC |
| 4 · Change in ownership | Aug 18, 2025 | Insider trade | SEC |
| 10-Q · Quarterly report | Aug 7, 2025 | Quarterly report | SEC |
| 8-K · Current report | Aug 7, 2025 | Results | SEC |
| 4 · Change in ownership | Jul 16, 2025 | Insider trade | SEC |
| EFFECT · Notice that a registration is effective | Jul 10, 2025 | Other filings | SEC |
| EFFECT · Notice that a registration is effective | Jul 10, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Jul 7, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Jul 7, 2025 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Jul 7, 2025 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Jul 7, 2025 | Other filings | SEC |
| S-3 · Registration statement | Jul 1, 2025 | Offer document | SEC |
| S-3 · Registration statement | Jul 1, 2025 | Offer document | SEC |
| 8-K · Current report | Jun 18, 2025 | Meeting outcome | SEC |
| 4 · Change in ownership | Jun 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 18, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jun 16, 2025 | Other filings | SEC |
| 8-K · Current report | Jun 2, 2025 | Current report | SEC |
| 4 · Change in ownership | May 19, 2025 | Insider trade | SEC |
| 10-Q · Quarterly report | May 8, 2025 | Quarterly report | SEC |
| 8-K · Current report | May 8, 2025 | Results | SEC |
| ARS · Annual report to shareholders | Apr 24, 2025 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 24, 2025 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 24, 2025 | Meeting notice | SEC |
| 4 · Change in ownership | Apr 16, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 17, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Mar 14, 2025 | Other filings | SEC |
| 4 · Change in ownership | Mar 13, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 13, 2025 | Insider trade | SEC |
| S-8 · Registration statement for employee plans | Mar 11, 2025 | Offer document | SEC |
| 10-K · Annual report | Mar 11, 2025 | Annual report | SEC |
| 8-K · Current report | Mar 11, 2025 | Results | SEC |
| 4 · Change in ownership | Mar 5, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Mar 5, 2025 | Insider trade | SEC |
| 8-K · Current report | Mar 3, 2025 | Current report | SEC |
| SCHEDULE 13G · Big-stake notice | Feb 13, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Feb 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 4, 2025 | Insider trade | SEC |
| 8-K · Current report | Jan 10, 2025 | Current report | SEC |
| SC 13G · Big-stake notice | Nov 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Nov 13, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 12, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Nov 7, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Nov 7, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Nov 7, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Nov 7, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Nov 7, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Nov 7, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Nov 7, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Nov 7, 2024 | Insider trade | SEC |
| 10-Q · Quarterly report | Nov 7, 2024 | Quarterly report | SEC |
This page holds 200 of 254 filings. Open Filings
Cap table
Built by 6ix from Rapport Therapeutics, Inc.’s releases · as of Nov 4, 2026
- Common shares
- 59,279,630
- Fully diluted
- 59,279,630
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 59,279,630 | Nov 2, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 59,279,630 |
| Nov 2, 2026 | 60,708,201 |
| Nov 2, 2026 | 59,279,630 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| James Healy Other companies: Seaport Therapeutics, Inc. (Director · Since at least Apr 30, 2026); BioAge Labs, Inc. (Director · Since at least Sep 25, 2024); ArriVent BioPharma, Inc. (Director · Since at least Jan 25, 2024); Y mAbs Therapeutics (Director · Since at least Jun 12, 2019); CinCor Pharma Inc (Director · Jan 6, 2022 – Nov 28, 2022 · Past); Bolt Biotherapeutics, Inc. (Director · Feb 4, 2021 – Jun 12, 2024 · Past); Karuna Therapeutics Inc (Director · Jun 27, 2019 – Mar 18, 2024 · Past); Coherus Oncology, Inc. (Director · May 22, 2019 – Jan 7, 2022 · Past); Natera, Inc. (Director · Sep 14, 2018 – Apr 25, 2025 · Past) | Director · Since at least Jun 6, 2024 |
| Steve Paul Other companies: Seaport Therapeutics, Inc. (Director · Since at least Apr 30, 2026); Karuna Therapeutics Inc (Director · Jun 27, 2019 – Mar 18, 2024 · Past); Alnylam Pharmaceuticals, Inc. (Director · Jun 3, 2016 – Apr 1, 2022 · Past); Sigma-Aldrich Corp (Director · Nov 18, 2015 – Nov 18, 2015 · Past); Voyager Therapeutics, Inc. (Director · Nov 10, 2015 – Jun 3, 2021 · Past); Sage Therapeutics Inc (Director · Jul 1, 2015 – Jan 3, 2024 · Past) | Director · Since at least Jun 6, 2024 |
| Troy Ignelzi Other companies: Harmony Biosciences Holdings, Inc. (Director · Since at least Apr 2, 2026); Contineum Therapeutics, Inc. (Chief Financial Officer, Rapport Therapeutics, Inc. · Since at least May 20, 2024); CinCor Pharma Inc (Director · Jan 6, 2022 – Feb 24, 2023 · Past); Karuna Therapeutics Inc (Chief Financial Officer · Jun 27, 2019 – Aug 22, 2023 · Past); Scpharmaceuticals Inc (Chief Financial Officer · Nov 16, 2017 – Jan 17, 2018 · Past) | Chief Financial Officer · Since at least Jun 6, 2024 |
| Abraham Ceesay Other companies: Charles River Laboratories International, Inc. (Director · Since at least May 20, 2025); Pacira BioSciences, Inc. (Director · Since at least Oct 6, 2023); Cerevel Therapeutics Holdings Inc (President · Aug 5, 2022 – Feb 6, 2023 · Past) | Chief Executive Officer, Director · Since at least Jun 6, 2024 |
| John M. Maraganore Other companies: Beam Therapeutics Inc. (Board Member · Since at least Nov 5, 2026); Alnylam Pharmaceuticals, Inc. (Director · Since at least Mar 3, 2026); Instil Bio, Inc. (Director · Jun 11, 2025 – Nov 4, 2026 · Past) | Venture Partner, ARCH Venture Partners and Atlas Ventures · Since at least Oct 22, 2026 |
| Ramiro Sanchez Other companies: Alto Neuroscience, Inc. (Director · Since at least Aug 12, 2025); Cerevel Therapeutics Holdings Inc (Chief Medical Officer · Oct 27, 2020 – Aug 1, 2024 · Past) | Director · Since at least Nov 7, 2024 |
| Terry-Ann Burrell Other companies: Recursion Pharmaceuticals, Inc. (Director · Apr 15, 2021 – Jul 1, 2024 · Past); Beam Therapeutics Inc. (Chief Financial Officer · Feb 5, 2020 – Apr 26, 2024 · Past) | Director · Jun 6, 2024 – Jun 6, 2024 · Past |
| Cheryl Gault Other companies: Cyclerion Therapeutics, Inc. (Chief Operating Officer · Jan 1, 2021 – Jan 20, 2022 · Past) | Chief Operating Officer · Since at least Jun 6, 2024 |
| Paul M Silva Other companies: Nurix Therapeutics, Inc. (Director · Since at least May 19, 2025) | Director · Since at least Jun 17, 2025 |
| Abe Ceesay | President · Since at least Jan 9, 2025 |
All 15 people
| Person | Seat |
|---|---|
| David Bredt | Chief Scientific Officer · Since at least Jun 6, 2024 |
| Jeffrey Sevigny | Chief Medical Officer · Since at least Apr 1, 2025 |
| Kathy Wilkinson | Chief People Officer · Since at least Nov 4, 2026 |
| Reid Huber | Partner, Third Rock Ventures · Since at least Nov 5, 2026 |
| Swamy Yeleswaram | Chief Development Officer · Since at least Nov 14, 2024 |
Log in to ask 6ix AI your own questions about Rapport Therapeutics, Inc.